Badana, Luvin C.
HRN: 23-56-88 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/11/2024
CEFUROXIME 1.5GM (VIAL)
07/11/2024
07/18/2024
IV
1.5grams
Q8H
Fistula-in-Ano
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes